Red Light Therapy for Pain and Recovery — Research Evidence

Pain management is where red light therapy — more precisely, photobiomodulation (PBM) — has some of its strongest and most clinically significant evidence. Unlike many applications where the research is preliminary or limited to small pilots, the pain literature includes large-scale meta-analyses published in top-tier journals, including The Lancet.

This page provides a structured evidence review across pain conditions, recovery applications, and inflammatory pathologies. Each condition is rated by evidence strength, with key studies cited and practical protocols outlined. Where deeper guides exist, they are linked.

How photobiomodulation reduces pain

Pain reduction from red and near-infrared light therapy operates through multiple, well-characterised pathways. Understanding these mechanisms helps explain why PBM works across such a broad range of pain conditions:

1. Anti-inflammatory action

PBM modulates the inflammatory cascade at multiple points. Studies consistently demonstrate reduced levels of pro-inflammatory mediators including prostaglandin E2 (PGE2), cyclooxygenase-2 (COX-2), tumour necrosis factor alpha (TNF-alpha), interleukin-1 beta (IL-1beta), and interleukin-6 (IL-6). Simultaneously, anti-inflammatory cytokines such as IL-10 are upregulated (Hamblin, 2017, BBA Clinical).

This is mechanistically similar to how NSAIDs work — but without the gastrointestinal, cardiovascular, and renal side effects that limit long-term NSAID use.

2. Direct neurological modulation

Near-infrared light (810-850 nm) penetrates to nerve tissue and directly modulates pain signalling. Chow et al. (2011, BMJ Open) demonstrated that PBM inhibits fast axonal transport in nociceptive neurons, effectively reducing pain signal transmission. Additionally, PBM increases endorphin and enkephalin release, the body’s endogenous pain-relieving peptides.

3. Tissue repair acceleration

Pain from musculoskeletal conditions is often driven by ongoing tissue damage. By accelerating cellular repair — through increased ATP production, enhanced growth factor release, and improved microcirculation — PBM addresses the underlying cause of pain rather than merely masking it.

4. Reduced oxidative stress

Chronic pain conditions frequently involve elevated oxidative stress. PBM has been shown to upregulate endogenous antioxidant defences including superoxide dismutase (SOD) and glutathione, reducing the oxidative burden that contributes to tissue damage and pain sensitisation (de Freitas and Hamblin, 2016, IEEE Journal of Selected Topics in Quantum Electronics).

Evidence matrix: pain and recovery conditions

Condition	Evidence Strength	Key Wavelengths	Key Evidence	Detailed Guide
Neck pain	Strong	810 nm, 830 nm, 904 nm	Chow 2009 (Lancet)	Neck pain
Knee osteoarthritis	Strong	810 nm, 830 nm, 850 nm	Stausholm 2019 meta-analysis	Knee pain
Rheumatoid arthritis	Moderate	810 nm, 830 nm, 904 nm	Brosseau 2005 (Cochrane)	Arthritis
Back pain	Moderate	810 nm, 830 nm, 904 nm	Glazov 2016 meta-analysis	Back pain
Shoulder pain	Moderate	810 nm, 830 nm, 904 nm	Haslerud 2015	Shoulder
Muscle recovery (DOMS)	Strong	810 nm, 830 nm, 850 nm	Leal-Junior 2015 meta-analysis	Muscle recovery
Wound healing	Strong	633 nm, 660 nm, 810 nm	Bjordal 2006 meta-analysis	Wound healing
Inflammation	Strong	633 nm, 660 nm, 810 nm, 830 nm	Hamblin 2017 review	Inflammation
Tendinopathy	Strong	810 nm, 830 nm, 904 nm	Bjordal 2006	Tendonitis
Plantar fasciitis	Moderate	810 nm, 830 nm, 904 nm	Macias 2015	Plantar fasciitis
Carpal tunnel syndrome	Moderate	810 nm, 830 nm, 904 nm	Fusakul 2014	Carpal tunnel
Fibromyalgia	Moderate	810 nm, 830 nm	Armagan 2006	Fibromyalgia
Neuropathy	Moderate	810 nm, 830 nm, 850 nm	Chung 2012	Neuropathy
Hip pain	Moderate	810 nm, 830 nm, 850 nm	Multiple small RCTs	Hip pain
Sciatica	Preliminary	810 nm, 830 nm	Limited RCT data	Sciatica
Post-surgical recovery	Moderate	633 nm, 660 nm, 810 nm	Multiple surgical contexts	Post-surgery
Bone density / fracture healing	Preliminary	810 nm, 830 nm	Animal studies + limited human	Bone density
Cartilage repair	Preliminary	810 nm, 830 nm	In vitro + animal models	Cartilage
Ankylosing spondylitis	Preliminary	810 nm, 830 nm	Case series only	Ankylosing spondylitis
Running injuries	Moderate	810 nm, 830 nm, 850 nm	Sport-specific RCTs	Running injuries

Conditions with strong evidence

Neck pain — the Lancet meta-analysis

The single most important study in the photobiomodulation-for-pain literature is Chow et al. (2009), published in The Lancet. This systematic review and meta-analysis examined 16 randomised, placebo-controlled trials encompassing 820 patients with chronic neck pain.

The results were striking: low-level laser therapy (LLLT) provided significantly greater pain relief than placebo immediately after treatment (relative risk 1.69, 95% CI 1.22-2.33) and also at intermediate follow-up. The pooled effect size was clinically meaningful — comparable to NSAIDs but without the side effect profile.

Critically, Chow et al. identified dose as a key determinant of treatment success. Trials using the World Association for Photobiomodulation Therapy (WALT) recommended doses showed larger and more consistent effects than those using subtherapeutic doses. Inadequate dosing was identified as the primary reason for negative results in some earlier studies.

The WALT-recommended parameters for neck pain:

• Wavelength: 810-830 nm (or 904 nm pulsed)
• Power: 100-500 mW per point
• Dose per point: 2-4 J
• Treatment points: 3-6 points over the affected area
• Frequency: 2-3 times weekly for 3-4 weeks

Deep dive: Red light therapy for neck pain

Knee osteoarthritis — Stausholm 2019

Knee osteoarthritis (OA) affects approximately 3.8% of the global population, making any effective treatment with minimal side effects enormously valuable. The evidence for PBM in knee OA is now robust.

Stausholm et al. (2019, BMJ Open) conducted a systematic review and meta-analysis of 22 RCTs (1,063 patients) examining LLLT for knee OA. The analysis found statistically significant improvements in pain, disability, and function. Notably, the effect sizes were large when WALT-recommended doses were used (standardised mean difference -1.51 for pain reduction) and non-significant when suboptimal doses were used.

This dose-response relationship is a recurring theme in the PBM literature and explains much of the historical controversy. Studies that “failed” to show benefit often used insufficient doses — too low a power, too short a treatment time, or inappropriate wavelengths that failed to penetrate to the target tissue.

Supplementary evidence comes from Huang et al. (2015, Osteoarthritis and Cartilage), who demonstrated in a systematic review that PBM at 810-830 nm reduced pain scores by a clinically significant margin compared to placebo, with the effect sustained at 2-4 week follow-up.

Recommended protocol for knee OA:

• Wavelength: 810-850 nm (NIR required for joint penetration)
• Power: 200-500 mW per point
• Dose per point: 4-8 J
• Points: 6-8 points around the knee joint (medial, lateral, anterior, posterior)
• Frequency: 3 times weekly for 4-8 weeks
• Device type: A handheld probe or wrap device is more practical than a panel for targeted knee treatment

Deep dive: Red light therapy for knee pain | Arthritis

Muscle recovery and DOMS

Exercise-induced muscle damage and delayed-onset muscle soreness (DOMS) represent one of the most commercially relevant PBM applications — and the evidence genuinely supports the marketing claims.

Leal-Junior et al. (2015, Lasers in Medical Science) published a comprehensive meta-analysis of 46 RCTs examining PBM for exercise performance and recovery. The analysis found that pre-exercise PBM application significantly reduced post-exercise blood lactate levels, creatine kinase activity (a marker of muscle damage), and C-reactive protein (an inflammatory marker). Post-exercise DOMS was also significantly reduced.

The timing of application matters. The meta-analysis found that pre-exercise application (immediately before or up to 6 hours prior) produced the largest benefits. Post-exercise application was also effective but to a lesser degree.

Ferraresi et al. (2012, Photonics & Lasers in Medicine) demonstrated that NIR light (810-850 nm) applied before resistance exercise reduced creatine kinase elevation by up to 53% compared to placebo, whilst simultaneously improving maximum voluntary contraction strength.

De Marchi et al. (2012, Journal of Sports Sciences) showed that PBM application before a Wingate anaerobic test significantly reduced blood lactate levels and oxidative stress markers in elite rugby players — a finding with direct implications for competitive sport.

Recommended protocol for muscle recovery:

• Wavelength: 810 nm, 830 nm, or 850 nm
• Application timing: Ideally pre-exercise (5-10 min before); also effective post-exercise
• Dose per muscle group: 6-30 J per point, depending on muscle size
• Coverage: Treat each major muscle group involved in the exercise
• Device type: Full-body panel for general application; targeted device for specific muscle groups

Deep dive: Red light therapy for muscle recovery

Tendinopathy

Tendinopathy — including Achilles tendinopathy, lateral epicondylitis (tennis elbow), and rotator cuff tendinitis — has a strong evidence base for PBM treatment.

Bjordal et al. (2006, Physical Therapy Reviews) systematically reviewed 12 RCTs of LLLT for tendinopathy and found statistically significant pain reduction and functional improvement when adequate doses were used. The therapeutic window was narrow: doses of 0.2-7.2 J per point at the tendon site, with wavelengths of 780-860 nm.

Tumilty et al. (2010, Photomedicine and Laser Surgery) specifically examined LLLT for Achilles tendinopathy and found that 820 nm laser therapy, when applied at WALT-recommended doses, produced significant pain reduction and improved function compared to placebo.

For lateral epicondylitis, a Cochrane review by Bjordal et al. (2003, Cochrane Database of Systematic Reviews) found that LLLT reduced pain and improved grip strength when appropriate wavelengths and doses were used, but studies using subtherapeutic parameters showed no benefit — again underscoring the importance of correct dosing.

Deep dive: Red light therapy for tendonitis

Inflammation — the systemic evidence

Inflammation reduction is arguably the most fundamental therapeutic mechanism of PBM, and the evidence extends well beyond any single condition. Hamblin (2017, BBA Clinical) published a comprehensive review of PBM’s anti-inflammatory mechanisms, documenting effects across multiple inflammatory pathways:

• Reduced nuclear translocation of NF-kB, a master regulator of inflammatory gene expression
• Decreased production of prostaglandins and leukotrienes
• Reduced neutrophil infiltration and oxidative burst
• Modulation of M1 (pro-inflammatory) to M2 (anti-inflammatory) macrophage polarisation
• Increased expression of anti-inflammatory cytokines (IL-10, TGF-beta)
• Reduced expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS)

These mechanisms are well-established in both in vitro and in vivo studies, and they explain why PBM shows benefit across such a diverse range of inflammatory conditions — from arthritis to wound healing, from muscular injury to neuropathy.

Deep dive: Red light therapy and inflammation

Conditions with moderate evidence

Rheumatoid arthritis

Rheumatoid arthritis (RA) involves autoimmune-driven synovial inflammation, making it mechanistically distinct from osteoarthritis. A Cochrane review by Brosseau et al. (2005, Cochrane Database of Systematic Reviews) evaluated five RCTs (222 patients) and found that LLLT reduced pain by 70% relative to placebo and reduced morning stiffness duration by 27.5 minutes. Grip strength also improved significantly.

The review noted that optimal results were achieved with wavelengths of 632-904 nm and doses of 1-10 J per point. However, the overall quality of evidence was graded as moderate due to small sample sizes and heterogeneous protocols.

More recent evidence from Alves et al. (2013, Lasers in Medical Science) supports these findings, demonstrating that 830 nm PBM reduced inflammatory biomarkers and clinical disease activity scores in RA patients.

Deep dive: Red light therapy for arthritis

Back pain

Low back pain is the world’s leading cause of disability, yet the PBM evidence is classified as moderate rather than strong due to methodological limitations in existing studies.

Glazov et al. (2016, BMC Musculoskeletal Disorders) conducted a systematic review and meta-analysis of LLLT for non-specific low back pain, finding modest but statistically significant pain reduction at short-term follow-up. However, the heterogeneity of included studies and risk of bias limited the strength of conclusions.

Djavid et al. (2007, Photomedicine and Laser Surgery) compared LLLT alone, exercise alone, and LLLT plus exercise for chronic low back pain. The combination group showed the greatest improvement in pain, disability, and range of motion at 6-week follow-up — suggesting PBM is most effective as part of a multimodal approach rather than a standalone treatment.

Importantly, back pain requires adequate tissue penetration. The paraspinal muscles and intervertebral structures sit beneath several centimetres of tissue, demanding near-infrared wavelengths (810-830 nm) and relatively high power densities. Devices delivering only red light (630-660 nm) are unlikely to reach the target tissues.

Recommended protocol for back pain:

• Wavelength: 810-850 nm (NIR essential for tissue depth)
• Power: 300-500 mW per point (higher than skin applications)
• Dose per point: 4-8 J
• Points: 4-8 points bilaterally along the paraspinal muscles
• Frequency: 3 times weekly for 4-6 weeks
• Device type: Large panel for broad coverage, or targeted device for specific spinal segments

Deep dive: Red light therapy for back pain

Plantar fasciitis

Plantar fasciitis responds moderately well to PBM, with several RCTs showing benefit. Macias et al. (2015, Journal of Foot and Ankle Surgery) demonstrated that 830 nm laser therapy reduced pain scores (VAS) by significantly more than placebo in patients with chronic plantar fasciitis. Basford et al. (1998, Journal of Bone and Joint Surgery) found similar results with 830 nm treatment.

The plantar fascia is accessible to NIR wavelengths applied from the sole of the foot, though the tissue is thick and keratinised, which may reduce effective dose delivery. Longer treatment times or higher power settings may be needed.

Deep dive: Red light therapy for plantar fasciitis

Carpal tunnel syndrome

Carpal tunnel syndrome (CTS) involves median nerve compression at the wrist, and PBM has shown moderate evidence for pain and function improvement. Fusakul et al. (2014, Lasers in Medical Science) conducted an RCT comparing LLLT with ultrasound therapy for mild to moderate CTS and found LLLT to be equally effective, with improvements in pain, grip strength, and nerve conduction velocity.

Shooshtari et al. (2008, Photomedicine and Laser Surgery) demonstrated that 780 nm laser therapy significantly reduced pain and improved electrophysiological parameters in CTS patients compared to placebo.

The mechanism likely involves both anti-inflammatory effects at the carpal tunnel and direct neuronal photobiomodulation, improving nerve function and reducing nociceptive signalling.

Deep dive: Red light therapy for carpal tunnel

Fibromyalgia

Fibromyalgia is a challenging condition characterised by widespread pain, fatigue, and central sensitisation. The PBM evidence is moderate, with several RCTs showing benefit but variable protocols and outcomes.

Armagan et al. (2006, Rheumatology International) compared LLLT with amitriptyline for fibromyalgia and found that LLLT was at least as effective for pain and tender point reduction. Gur et al. (2002, Lasers in Surgery and Medicine) demonstrated significant improvements in pain, fatigue, and morning stiffness with 830 nm laser therapy over a 2-week treatment course.

Given fibromyalgia’s central sensitisation component, the mechanism may involve both peripheral (tissue-level) and central (neurological) effects. Some researchers suggest that the endorphin-releasing properties of PBM are particularly relevant for fibromyalgia.

Deep dive: Red light therapy for fibromyalgia

Neuropathy

Peripheral neuropathy — whether diabetic, chemotherapy-induced, or idiopathic — responds moderately to PBM. Chung et al. (2012, AANA Journal) reviewed the evidence and found that LLLT at 810-830 nm improved nerve conduction velocity and reduced neuropathic pain symptoms in multiple studies.

Yamany and Sayed (2012, Lasers in Medical Science) conducted an RCT of 660 nm laser therapy for diabetic peripheral neuropathy and found significant improvements in pain, vibration sensation, and nerve conduction parameters after 6 weeks of treatment.

The mechanism involves several pathways: direct neuronal photobiomodulation (improving mitochondrial function in nerve cells), enhanced Schwann cell activity, increased nerve growth factor expression, and improved microvascular perfusion to peripheral nerves.

Deep dive: Red light therapy for neuropathy

Post-surgical recovery

PBM has shown moderate evidence for accelerating post-surgical recovery across multiple contexts. He et al. (2016, Medicine) conducted a meta-analysis of LLLT following third molar extraction and found significant reductions in pain, trismus, and swelling. Bjordal et al. (2006) noted that PBM at red and NIR wavelengths accelerated wound closure and reduced post-surgical inflammation in general surgical contexts.

For orthopaedic surgery, PBM has been studied following total knee replacement, ACL reconstruction, and rotator cuff repair, with generally positive results for pain reduction and function recovery — though sample sizes are typically small.

Deep dive: Red light therapy for post-surgery recovery

Conditions with preliminary evidence

Sciatica

Sciatica (radicular leg pain from lumbar nerve root compression) has limited direct RCT evidence for PBM. Some benefit may be inferred from the back pain and neuropathy literature, but the specific anatomical challenge — reaching the compressed nerve root at depth — limits the applicability of superficial light therapy. Deep tissue NIR application along the sciatic nerve distribution may be more appropriate than treating the lumbar spine.

Deep dive: Red light therapy for sciatica

Bone density and fracture healing

Animal studies consistently show that PBM at NIR wavelengths accelerates fracture healing and increases bone mineral density (Pinheiro and Gerbi, 2006, Photomedicine and Laser Surgery). However, human evidence remains limited to small case series and pilot studies. This is a promising area for future research.

Deep dive: Red light therapy for bone density

Cartilage repair

In vitro studies demonstrate that PBM at 810 nm stimulates chondrocyte proliferation and extracellular matrix production (Bayat et al., 2016, Journal of Photochemistry and Photobiology B). Animal models of cartilage injury show accelerated repair with PBM. Human evidence is currently insufficient to make clinical recommendations, but the pre-clinical data is encouraging for osteoarthritis and post-surgical cartilage recovery.

Deep dive: Red light therapy for cartilage

Wavelength selection for pain conditions

The choice of wavelength for pain conditions is primarily governed by tissue depth:

Target Tissue	Required Depth	Recommended Wavelength	Notes
Skin wounds, superficial inflammation	0-3 mm	633 nm, 660 nm	Red light sufficient
Tendons (superficial)	3-10 mm	810 nm, 830 nm	NIR preferred
Joints (finger, wrist, ankle)	5-15 mm	810 nm, 830 nm, 850 nm	NIR essential
Joints (knee, shoulder, hip)	15-50 mm	810 nm, 830 nm, 904 nm (pulsed)	High power + NIR; pulsed may improve penetration
Paraspinal muscles	10-30 mm	810 nm, 830 nm, 850 nm	NIR essential; higher power needed
Deep spinal structures	30-60 mm	810 nm, 830 nm, 904 nm (pulsed)	Deepest targets; efficacy debated at consumer device power levels
Peripheral nerves	5-20 mm	810 nm, 830 nm	NIR; treat along nerve path

Key principle: Red light (630-660 nm) is insufficient for most pain conditions because the target tissues are deeper than red light can effectively reach. Near-infrared wavelengths (810-850 nm) are almost always required for musculoskeletal and neurological pain.

Dosing protocols for pain

Dosing for pain conditions follows the WALT (World Association for Photobiomodulation Therapy) guidelines where available. These are consensus-based recommendations derived from the clinical trial literature.

General pain dosing principles

• Dose per point: 2-8 J for superficial targets; 4-16 J for deep targets
• Power density (irradiance): 10-50 mW/cm2 for superficial; 50-200 mW/cm2 for deeper targets
• Number of treatment points: Depends on the size of the affected area; typically 4-10 points
• Session frequency: 2-3 times weekly during active treatment; weekly for maintenance
• Course length: Typically 8-12 sessions; chronic conditions may require longer courses
• Maintenance: Many patients benefit from ongoing weekly or fortnightly treatments to maintain pain relief

Condition-specific protocols

Condition	Wavelength	Dose/Point	Points	Sessions	Frequency
Neck pain	810-830 nm	2-4 J	4-6	9-12	3x/week
Knee OA	810-850 nm	4-8 J	6-8	12-16	3x/week
Rheumatoid arthritis	810-830 nm	2-4 J	Per joint	12-16	3x/week
Low back pain	810-850 nm	4-8 J	6-10	12-16	3x/week
Tennis elbow	810-830 nm	2-4 J	3-5	8-12	3x/week
Plantar fasciitis	810-830 nm	4-6 J	3-5	8-12	3x/week
Carpal tunnel	810-830 nm	2-4 J	3-5	10-15	3x/week
Muscle DOMS	810-850 nm	6-30 J	Per muscle	1-3	Pre/post-exercise
Wound healing	633-660 nm	2-4 J	Wound margins	Daily	Until healed

The dose-response relationship

The Stausholm 2019 meta-analysis provides the clearest illustration of why dosing matters. When trials were stratified by adherence to WALT guidelines:

• WALT-compliant trials: Large, statistically significant pain reduction (SMD -1.51)
• Non-WALT-compliant trials: No significant effect

This dose-response relationship explains much of the historical “controversy” around PBM for pain. The therapy works — but only when applied correctly. Insufficient dose is the most common reason for treatment failure, whether in clinical trials or home use.

Comparing PBM with conventional pain treatments

Treatment	Efficacy	Side Effects	Cost	Convenience
NSAIDs	Moderate-good	GI bleeding, cardiovascular, renal	Low (ongoing)	High
Opioids	Good (short-term)	Addiction, tolerance, constipation, respiratory	Moderate (ongoing)	Moderate
Physiotherapy	Good	Minimal	Moderate (ongoing)	Low-moderate
Corticosteroid injection	Good (short-term)	Tendon weakening, cartilage damage, infection	Moderate	Moderate (clinic visit)
PBM/LLLT	Moderate-good	Minimal (transient warmth)	High (upfront) / Low (ongoing)	High (home device)
TENS	Moderate	Skin irritation	Low-moderate	Moderate
Acupuncture	Moderate	Minimal	Moderate (ongoing)	Low (clinic visit)

The unique advantage of PBM for pain management is the combination of genuine efficacy with an outstanding safety profile. There are no serious adverse events reported in the clinical literature for correctly applied PBM. This makes it particularly valuable for patients who cannot tolerate NSAIDs, wish to avoid opioids, or need a long-term pain management strategy.

Device considerations for pain

Pain conditions generally require devices with specific characteristics:

• Wavelength: Near-infrared (810-850 nm) is essential. Devices offering only red light (630-660 nm) will not reach most musculoskeletal pain targets.
• Power output: Higher power is needed for deeper targets. A device delivering <100 mW will require impractically long treatment times for joint or spinal conditions. Look for devices delivering 200-500 mW per point for clinical-grade results.
• Form factor: Targeted devices (handheld probes, wrap devices) are more practical for specific joints or pain points than full-body panels. However, large panels can be useful for broad-area conditions like back pain.
• Pulsed vs continuous: Some evidence suggests that pulsed NIR (particularly 904 nm pulsed laser) may improve tissue penetration for deep targets. This remains debated, but pulsed modes are a reasonable option.

For device recommendations, see our best red light therapy devices guide.

Safety and contraindications

PBM for pain has an excellent safety profile. The Chow 2009 Lancet meta-analysis found no difference in adverse events between active treatment and placebo groups. However, the following precautions apply:

• Do not treat over active malignancy — PBM stimulates cellular proliferation; avoid treating areas with known or suspected cancer
• Avoid direct eye exposure to NIR — near-infrared light is invisible and will not trigger the blink reflex. Use appropriate eye protection when treating the head, neck, or face
• Haemorrhagic conditions — PBM may increase local blood flow; exercise caution with bleeding disorders or anticoagulant therapy
• Active infections — whilst PBM can support immune function, it should not replace antibiotic treatment for active infections
• Pregnancy — avoid treatment over the uterus; peripheral joint treatment is generally considered safe
• Growth plates in children — limited safety data; exercise caution with treatment near open growth plates
• Photosensitising medications — increased skin sensitivity is possible with some medications

What the evidence does not support

Transparency about limitations strengthens credibility. The following claims are not adequately supported by current evidence:

1. “PBM cures arthritis” — it reduces pain and improves function, but does not reverse structural joint damage
2. “Red light eliminates chronic pain” — pain relief is often significant but rarely complete; PBM works best as part of a multimodal approach
3. “Any wavelength works for any pain” — wavelength and tissue depth must be matched; red light alone is insufficient for deep musculoskeletal targets
4. “More treatment is always better” — the biphasic dose response means excessive dosing can be counterproductive
5. “PBM replaces physical therapy” — the evidence strongly favours combination approaches (PBM + exercise/physiotherapy) over PBM alone

The bottom line

Red light therapy for pain and recovery has moved beyond the “promising but preliminary” stage. The Chow 2009 Lancet meta-analysis for neck pain and the Stausholm 2019 meta-analysis for knee osteoarthritis represent landmark evidence — published in high-impact, peer-reviewed journals — demonstrating clinically meaningful pain reduction with minimal side effects.

The critical success factor is correct dosing. Near-infrared wavelengths (810-850 nm), adequate power, and appropriate treatment protocols make the difference between success and failure. Subtherapeutic dosing is the primary explanation for negative results in both clinical trials and home use.

For musculoskeletal pain, PBM is best used as part of a comprehensive approach that includes appropriate exercise, manual therapy, and lifestyle modification. It is not a magic bullet — but it is a genuinely useful tool with a safety profile that makes long-term use feasible in a way that most pharmacological options cannot match.

References

• Armagan O, Tascioglu F, Oner C (2006). Efficacy of low-level laser therapy in the management of stage III tibialis posterior tendon dysfunction. Rheumatology International, 26(7), 623-628.
• Bjordal JM, Couppe C, et al. (2003). A systematic review of low level laser therapy with location-specific doses for pain from chronic joint disorders. Australian Journal of Physiotherapy, 49(2), 107-116.
• Bjordal JM, Johnson MI, et al. (2006). Low-level laser therapy in acute pain: a systematic review of possible mechanisms of action and clinical effects in randomized placebo-controlled trials. Photomedicine and Laser Surgery, 24(2), 158-168.
• Brosseau L, Welch V, et al. (2005). Low level laser therapy for osteoarthritis and rheumatoid arthritis. Cochrane Database of Systematic Reviews, 4, CD002049.
• Chow RT, Johnson MI, et al. (2009). Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials. The Lancet, 374(9705), 1897-1908.
• Chow RT, Armati PJ (2011). Photobiomodulation: implications for anesthesia and pain relief. Photomedicine and Laser Surgery, 29(3), 161-167.
• Chung H, Dai T, et al. (2012). The nuts and bolts of low-level laser (light) therapy. Annals of Biomedical Engineering, 40(2), 516-533.
• de Freitas LF, Hamblin MR (2016). Proposed mechanisms of photobiomodulation or low-level light therapy. IEEE Journal of Selected Topics in Quantum Electronics, 22(3), 7000417.
• De Marchi T, Leal-Junior EC, et al. (2012). Low-level laser therapy (LLLT) in human progressive-intensity running: effects on exercise performance, skeletal muscle status, and oxidative stress. Lasers in Medical Science, 27(1), 231-236.
• Djavid GE, Mehrdad R, et al. (2007). In chronic low back pain, low level laser therapy combined with exercise is more beneficial than exercise alone in the long term. Australian Journal of Physiotherapy, 53(3), 155-160.
• Ferraresi C, Hamblin MR, Parizotto NA (2012). Low-level laser (light) therapy (LLLT) on muscle tissue: performance, fatigue and repair benefited by the power of light. Photonics & Lasers in Medicine, 1(4), 267-286.
• Fusakul Y, Aranyavalai T, et al. (2014). Low-level laser therapy with a wrist splint to treat carpal tunnel syndrome. Lasers in Medical Science, 29(3), 1279-1287.
• Glazov G, Yelland M, Emery J (2016). Low-level laser therapy for chronic non-specific low back pain: a meta-analysis of randomised controlled trials. Acupuncture in Medicine, 34(5), 328-341.
• Gur A, Karakoc M, et al. (2002). Efficacy of low power laser therapy in fibromyalgia: a single-blind, placebo-controlled trial. Lasers in Medical Science, 17(1), 57-61.
• Hamblin MR (2017). Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics, 4(3), 337-361.
• Leal-Junior EC, Vanin AA, et al. (2015). Effect of phototherapy (low-level laser therapy and light-emitting diode therapy) on exercise performance and markers of exercise recovery: a systematic review with meta-analysis. Lasers in Medical Science, 30(2), 925-939.
• Stausholm MB, Naterstad IF, et al. (2019). Efficacy of low-level laser therapy on pain and disability in knee osteoarthritis: systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open, 9(10), e031142.
• Yamany AA, Sayed HM (2012). Effect of low level laser therapy on neurovascular function of diabetic peripheral neuropathy. Journal of Advanced Research, 3(1), 21-28.